High-Flow Nasal Cannula Versus Conventional Oxygen Therapy After Extubation in Liver Transplantation

Effects of High-Flow Nasal Cannula Versus Conventional Oxygen Therapy After Extubation in Liver Transplantation: Matched Control Study.

Humidified oxygen therapy via high-flow nasal cannula (HFNC) is a recently available technique delivering heated and humidified high flow oxygen through simple nasal prongs. In immunocompetent patients HFNC can help generating low levels of Continuous Positive Airway Pressure (CPAP) due to the high flow of fresh gas, improving comfort and oxygenation, and it attenuates signs of respiratory distress compared with non-rebreathing oxygen face mask such as Venturi mask. Moreover, HFNC is considered to have several physiological advantages compared with other standard oxygen therapies, including the provision of positive end-expiratory pressure (PEEP), constant inspiratory oxygen fraction (FiO2), and good humidification. More importantly, it can reduce the anatomical dead space. For its advantages over conventional oxygen delivery system in patients undergoing abdominal surgery or Thoracoscopic Lobectomy, the investigators are currently and according to clinical practice using HFNC oxygen delivery in Liver transplantation after extubation, in our Post-Operative Intensive Care Unit (PICU).

Due to recipients' generally poor preoperative clinical conditions, the extensive surgical field and long operating times, post-operative respiratory disorders are very common after liver transplantation and they significantly contribute to the related morbidity and mortality, both in the acute postoperative stage and in the long term. Several factors are involved in the onset of postoperative pulmonary complications (PPCs), and many preoperative and intraoperative variables have been associated with different degrees of severity of respiratory impairment after liver transplantation. In the early stages after transplantation, pulmonary complications may prolong intubation time and increase the risk of systemic infective complications. Prolonged mechanical ventilation due to refractory respiratory failure is an extremely morbid event, as this event is a marker of poor recipient recovery, predisposes a recipient to long term ventilator dependency and predicts further complications.

In this matched control study, the investigators hypothesize that HFNC treatment might be superior to conventional oxygen therapy in terms of post-operative gas exchange and post-operative pulmonary complications for patients undergoing liver transplantation after extubation.

Study Overview

• Status: Completed
• Conditions: Gas Exchange
• Intervention / Treatment: Device: HFNC group

Detailed Description

Humidified oxygen therapy via high-flow nasal cannula (HFNC) is a recently available technique delivering heated and humidified high flow oxygen through simple nasal prongs. HFNC provides flows up to 60 L/min of heated air and oxygen at a constant fraction of inspired oxygen (FiO 2 ) up to 1.0. Several studies (1-3) have demonstrated that in immunocompetent patients HFNC can help generating low levels of CPAP due to the high flow of fresh gas, improving comfort and oxygenation, and it attenuates signs of respiratory distress compared with non-rebreathing oxygen face mask such as Venturi mask. Moreover, HFNC is considered to have several physiological advantages compared with other standard oxygen therapies, including the provision of positive end-expiratory pressure (PEEP), constant FiO2, and good humidification. More importantly, it can reduce the anatomical dead space. Several studies (1-4) demonstrated the efficacy of HFNC in reducing signs of respiratory distress compared to conventional oxygen delivery such as Venturi mask. For its advantages over conventional oxygen delivery system in patients undergoing abdominal surgery or Thoracoscopic Lobectomy (5,6), the investigators are currently and according to clinical practice using HFNC oxygen delivery in Liver transplantation after extubation, in our Post-Operative Intensive Care Unit (PICU).

Due to recipients' generally poor preoperative clinical conditions, the extensive surgical field and long operating times, post-operative respiratory disorders are very common after liver transplantation and they significantly contribute to the related morbidity and mortality, both in the acute postoperative stage and in the long term. Several factors are involved in the onset of postoperative pulmonary complications (PPCs), and many preoperative and intraoperative variables have been associated with different degrees of severity of respiratory impairment after liver transplantation (7). Although refinements in surgical techniques, antimicrobial prophylaxis, immunosuppression, anesthesia, and intensive care management have most likely altered the frequency and overall spectrum of post-liver transplantation respiratory disorders, it is still common for pulmonary infiltrates, atelectasis, pleural exudates, and other radiological abnormalities to be documented on chest X-ray at any time during a patient's stay at an intensive care unit. All of these respiratory disorders can affect lung compliance and alveolar gas exchange and, when severe, may necessitate tracheal intubation and mechanical ventilation. In the early stages after transplantation, pulmonary complications may prolong intubation time and increase the risk of systemic infective complications. Prolonged mechanical ventilation due to refractory respiratory failure is an extremely morbid event, as this event is a marker of poor recipient recovery, predisposes a recipient to long term ventilator dependency and predicts further complications.

In this patients with high risk of PPCs, the application of increased flow rates through HFNC could progressively reduce inspiratory effort and improve lung aeration, dynamic compliance and oxygenation as demonstrated in patients with acute hypoxemic respiratory failure (8).

In this matched control study, the investigators hypothesize that HFNC treatment might be superior to conventional oxygen therapy in terms of post-operative gas exchange and post-operative pulmonary complications for patients undergoing liver transplantation after extubation.

• Study Type: Observational
• Enrollment (Actual): 30

Contacts and Locations

Study Locations

• Italy
  • Rome, Italy, 00168
    • Fondazione Policlinico Gemelli

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

According with PICU Weaning protocol from mechanical ventilation, the investigators will be performed weaning trial and extubation after the evaluation of following conditions: 1) hemodynamic stability; 2) minimal ventilator support (pressure support ≤10 cm H2O with positive end-expiratory pressure ≤ 5 cm H2O); 3) adequate spontaneous breathing (Respiratory Rate < 25 breath.min-1).

Successfully completed the weaning trial, the patients will be extubated and will be received humidified oxygen by HFNC at the same FiO2 as the invasive mechanical ventilation with endotracheal tube and flow rate 60 L.min

Description

Inclusion Criteria:

• Liver transplantation surgery
• Presence of criteria to start a weaning trial

Exclusion Criteria:

• Patient < 18 years
• Need of cardiovascular resuscitation
• Glasgow Coma Score ≤ 8
• Hemodynamic instability

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
HFNC group; The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.	Device: HFNC group; Application of HFNC oxygen delivery after extubation.
Control Group; For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post- operative oxygenation	Evaluation of post-operative oxygenation measured at 1 hour after extubation	1 hour after extubaton

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Re-intubation rate	Evaluation of re-intubation incidence at 1 week after extubation	1 week after extubaton

Collaborators and Investigators

• Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Investigators: Principal Investigator: Giuliano Ferrone, MD, Fondazione Policlinico Gemelli

Publications and helpful links

General Publications

• Corley A, Rickard CM, Aitken LM, Johnston A, Barnett A, Fraser JF, Lewis SR, Smith AF. High-flow nasal cannulae for respiratory support in adult intensive care patients. Cochrane Database Syst Rev. 2017 May 30;5(5):CD010172. doi: 10.1002/14651858.CD010172.pub2.
• Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, Pesenti A. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017 May 1;195(9):1207-1215. doi: 10.1164/rccm.201605-0916OC.
• Futier E, Paugam-Burtz C, Godet T, Khoy-Ear L, Rozencwajg S, Delay JM, Verzilli D, Dupuis J, Chanques G, Bazin JE, Constantin JM, Pereira B, Jaber S; OPERA study investigators. Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA). Intensive Care Med. 2016 Dec;42(12):1888-1898. doi: 10.1007/s00134-016-4594-y. Epub 2016 Oct 22.
• Gaspari R, Spinazzola G, Ferrone G, Soave PM, Pintaudi G, Cutuli SL, Avolio AW, Conti G, Antonelli M. High-Flow Nasal Cannula Versus Standard Oxygen Therapy After Extubation in Liver Transplantation: A Matched Controlled Study. Respir Care. 2020 Jan;65(1):21-28. doi: 10.4187/respcare.06866. Epub 2019 Jul 3.

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2018
• Primary Completion (Actual): September 30, 2018
• Study Completion (Actual): December 31, 2018

Study Registration Dates

• First Submitted: February 5, 2018
• First Submitted That Met QC Criteria: February 15, 2018
• First Posted (Actual): February 22, 2018

Study Record Updates

• Last Update Posted (Actual): October 6, 2021
• Last Update Submitted That Met QC Criteria: September 28, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: Liver transplantation; Non invasive ventilation; Gas exchange
• Other Study ID Numbers: 1701/18

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No